In this video from the Macula Society meeting, Dilsher S. Dhoot, MD, FASRS, of California Retina Consultants, discusses ...

Belite Bio has recently begun a rolling New Drug Application submission to the U.S. FDA for tinlarebant, an oral therapy targeting Stargardt disease type 1, supported by Breakthrough Therapy, Fast ...

Early screening for geographic atrophy may help slow progression to foveal involvement. Collaborating with optometrists on geographic atrophy care is beneficial for patients. Healio spoke with Yasha S ...

A novel outcome measure for geographic atrophy, the Geographic Atrophy Weighted-by-Acuity Index, aligned with best-corrected visual acuity, showing better correlation and predictive accuracy than the ...

What is IZERVAY™?IZERVAY (avacincaptad pegol intravitreal solution) is a prescription eye injection, used to treat geographic atrophy (GA), the advanced form of dry age-related macular degeneration ...

Ocugen has synchronized pivotal clinical and regulatory milestones for its three retinal gene therapy programs into 2026 and early 2027, targeting retinitis pigmentosa, Stargardt disease, and ...

Age is a major risk factor for geographic atrophy (GA). As the eyes age, natural defenses weaken, blood flow may decline, and waste removal may slow, allowing deposits called drusen to build up.

Randomized trials of two FDA-approved intravitreal complement inhibitor injections showed that they slowed the progression of geographic atrophy, but failed to demonstrate functional benefits at 24 ...

Avacincaptad pegol (Zimura, IVERIC bio) slows the progression of geographic atrophy, results from a phase 3 clinical trial show, giving hope that there will soon be an approved treatment for one of ...